Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.
Conditions
Interventions
CD5024
Azelaic acid 15% Gel
Locations
50
United States
Total Skin and Beauty
Birmingham, Alabama, United States
Coastal Clinical Research, Inc.
Mobile, Alabama, United States
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States
Dermatology Specialists, Inc
Oceanside, California, United States
Integrated Research Group, Inc
Riverside, California, United States
Therapeutics Clinical Research
San Diego, California, United States
Start Date
December 1, 2011
Primary Completion Date
August 1, 2013
Completion Date
August 1, 2013
Last Updated
February 18, 2021
NCT01872715
NCT01933464
NCT01784133
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions